Binosto 70Mg Effervescent Tablet

DRUG2 trials

Sponsors

Labatec Pharma SA, 251 Hellenic Air Force & VA General Hospital

Conditions

Osteoporosis, PostmenopausalPostmenopausal Osteoporosis

Unknown Phase

Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

Labatec Pharma SAOsteoporosis, Postmenopausal

Start: 2018-02-25End: 2022-12-01Target: 80Updated: 2020-12-03

Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation

CompletedNCT04338529

251 Hellenic Air Force & VA General HospitalPostmenopausal Osteoporosis

Start: 2020-04-01End: 2024-11-01Updated: 2024-12-02